The 2-Minute Rule for Is ABBV-744 effective for hematologic cancers?
In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.- "Our study discovered the critical purpose with the KLF16/MYC regulatory axis in modulating t